CDC Clinical Practice Guideline for Prescribing Opioids–United States, 2022
The update process uses multiple key sources of input.
The 2016 Guideline was developed using the best available scientific evidence and followed a rigorous scientific process. The update to the Guideline is following a similar process and includes several opportunities for community and partner engagement. CDC highly values public engagement and has ensured there are multiple opportunities to hear from and incorporate feedback from patients with pain, caregivers, clinicians, and partners.
As I remember, there was no published proposed 2016 guidelines, the CDC attempted to keep all participants anonymous and there was NO PUBLIC COMMENT PERIOD. The people listed as involved with this revision are all most involved with addiction, substance abuse and overdoses.
the above is a direct quote from https://www.cdc.gov/opioids/guideline-update/index.html
This is on the first page of the revised CDC opiate dosing guidelines…
Wasn’t it Dr Chou on the first committee for the 2016 guidelines and AFTER THE FACT – admitted that he had conflict of interest ?
Here is where he is employed and the description of what they do:
https://www.ohsu.edu/evidence-based-practice-center/about
About Us
The Pacific Northwest Evidence-based Practice Center (EPC) conducts systematic reviews of health care topics for federal and state agencies, professional associations, and foundations. These reviews report the evidence from clinical research studies and the quality of that evidence for use by clinicians, employers, policymakers, researchers, and others in making decisions about the provision of health care services and health research. The reports may be used by public-and private-sector organizations to assist in improving the quality of health care, informing the development of clinical practice guidelines, and informing reimbursement and coverage policies. The Pacific Northwest EPC also participates in research on systematic review methods.
The EPC at Oregon Health & Science University was founded in 1997 under the directorship of Mark Helfand, MD, MPH, with funding from the Agency for Healthcare Research and Quality (AHRQ). Now under the leadership of Roger Chou, MD, the Pacific Northwest EPC is a collaboration of Oregon Health & Science University in Portland, Oregon, the University of Washington in Seattle, Washington, and Aggregate Analytics, Inc. in Fircrest, Washington. The EPC has received funding from AHRQ, the Drug Effectiveness Review Project, the National Institutes of Health, the Centers for Disease Control and Prevention, and various professional associations and foundations. The EPC at OHSU was previously known as the Oregon EPC.
Pacific Northwest EPC investigators come from a wide variety of disciplines within the partner institutions. Investigators with the EPC have a particular interest in diagnostic technology assessment, prevention, comparative effectiveness, evidence-based informatics, and health services research. In the past, faculty affiliated with the EPC have investigated a wide range of topics, including hepatitis, pressure ulcers, traumatic brain injury, pain management, drug effectiveness, cancer screening and treatment, HIV infection screening and prevention, telehealth, public reporting, menopausal symptoms, osteoporosis, vaginal birth after cesarean section, field triage of trauma, mental health, health equity, and substance use disorders.
CDC Clinical Practice Guideline for Prescribing Opioids–United States, 20221
Prepared by
Debbie Dowell, MD, MPH
https://www.cdc.gov/injury/pressroom/fullbios_subjectmatterexperts/bio_DebbieDowell.html
Chief Medical Officer, CDC Coronavirus Disease-2019 Response
Chief Clinical Research Officer, Division of Overdose Prevention, NCIPC
Areas of Expertise
- Opioid overdose prevention
- Opioid prescribing
Debbie Dowell, MD, MPH, is the chief medical officer for CDC’s COVID-19 Response and chief clinical research officer for CDC’s Division of Overdose Prevention at CDC’s Injury Center. She has served in various roles in CDC’s COVID-19 Response since February 2020, including deputy chief medical officer, chief medical/science officer, and associate editor of CDC’s COVID-19 Science Update.
Dr. Dowell completed her residency and chief residency in primary care internal medicine at Bellevue Hospital Center and the NYU School of Medicine, where she joined the faculty as a clinical assistant professor. She is board certified in internal medicine and served as an attending physician, providing care and supervising residents at a community health center in New York City. She currently volunteers at a community-based clinic, providing primary care for uninsured individuals in Georgia.
Previously, as chief medical officer for CDC’s Injury Center, Dr. Dowell led development of the CDC strategy to prevent opioid overdoses. She also served as advisor to New York City’s health commissioner. She has conducted research on quality and safety in medical care, the effects of clinical guidelines, and the effectiveness of interventions to prevent opioid overdose.
She received BA and MD degrees from Columbia University and an MPH degree from the Johns Hopkins Bloomberg School of Public Health. She is also a graduate of CDC’s Epidemic Intelligence Service (EIS).
Kathleen R. Ragan, MSPH
Christopher M. Jones, PharmD, DrPH
Christopher M. Jones, PharmD, DrPH, MPH. Deputy Director National Center for Injury Prevention and Control, Centers for Disease Control and Prevention Member, Rx Drug Abuse & Heroin Summit Advisory Board. Christopher M. Jones, PharmD, DrPH, MPH CAPT, US Public Health Service Deputy Director, CDC Injury Center Areas of Expertise Substance use and overdose prevention Suicide prevention ACEs …
Grant T. Baldwin, PhD, MPH
Director
Roger Chou, MD
Division of Overdose Prevention, National Center for Injury Prevention and Control, CDC, Atlanta, Georgia
Office of the Director, National Center for Injury Prevention and Control, CDC Atlanta, Georgia
Pacific Northwest Evidence–based Practice Center and Oregon Health & Science University, Portland, Oregon
Filed under: General Problems
It is inhumane to let chronic PAIN PTs. Suffer in silence and that is what is happening to me. I have had severe aggressive PIAN since 2003. For most of the time I was on PAIN MEDICATION and it worked very well. I don’t understand all the pain doctors ignoring us and giving us medication for drug addicts such as Belbuca or suboxone. Not only that pain and spine facilities are treating us as if we are drug seeking which is far from the truth.
I really hope the pain community steps up and fights this HARD. If they think they didn’t have it bad enough the first go around this one could be the Worst they’ve ever seen. Total CORRUPTION WITHIN THE CDC. ITS CLEAR THIS IS GENOCIDE AND ALL DONE INTENTIONALLY.